Abstract
Three patients with primary cutaneous B-cell lymphoma (one centroblastic/centrocytic, one centroblastic, one centrocytic; CBCL) and 16 with primary cutaneous T-cell lymphoma (14 mycosis fungoides, one Sézary syndrome and one T-pleomorphic lymphoma; CTCL) were treated with escalating doses (3 to 9-18 million units) of recombinant interferon-α-2a (rIFN-α 2a). Complete response (CR) was obtained in 8 patients (2 CBCL; 6 CTCL), partial response (PR) in 7 CTCL patients, and no response (NR) in 4 patients (1 CBCL; 3 CTCL). Four of 8 patients with CR had recurrent disease under maintenance treatment. Side effects observed in most patients included fever, fatigue, liver alterations, leucocytopenia and thrombocytopenia. All side effects were completely reversible with dose attenuation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Balkwill FR, 1989. Interferons. Lancet i: 1060–1063.
Bunn PA, KA Foon, DC Ihde et al., 1984. Recombinant leukocyte A interferon: An active agent in advanced cutaneous T cell lymphoma. Ann. Int. Med., 101: 484–487
Bunn PA, DC Ihde and KA Foon, 1987. Recombinant interferon alfa-2a: An active agent in advanced cutaneous T-cell lymphomas. Int. J. Cancer, Suppl. 1: 9–13.
Bunn PA, DC Ihde and KA Foon, 1986. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer, 57: 1689–1695.
Bunn PA and DA Norris, 1990. The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J. Invest. Dermatol., 95: 209S-212S.
Dreno B, WY Godefroy, M Fleischmann et al., 1989. Low-dose recombinant interferon-alpha in the treatment of cutaneous T-cell lymphoma. Br. J. Dermatol., 121: 543–544
Golomb HM, A Jacobs, A Fefer et al., 1986. Alpha-2 interferon therapy of hairy-cell leukemia: A multicentric study of 64 patients. J. Clin. Oncol., 4: 900–905
Hagberg H, L Juhlin, A Scheynius and U Tjernlund, 1988. Low dosage alpha-interferon treatment in patients with advanced cutaneous T-cell lymphoma. Eur. J. Haematol., 40: 31–34.
Halloway KB, FP Flowers and FA Ramos Caro, 1992. Therapeutic alternatives in cutaneous T-cell lymphoma. J. Am. Acad. Dermatol., 27: 367–378.
Ihde DC, R Steis, A Sausviller et al., 1987. Phase II trial of intermittent high dose recombinant interferon-α2a in mycosis fungoides and Sézary syndrome. Proc. Am. Assoc. Cancer Res., 28: 208.
Jones SE, 1990. Enigma of therapy for cutaneous T-cell lymphoma. J. Natl. Cancer Inst., 82: 169–170.
Kaplan EH, ST Rosen, DB Norris et al., 1990. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J. Natl. Cancer Inst., 82: 208–212.
Knobler RM, Trautinger F, Radaszkiewicz T et al., 1991. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J. Am. Acad. Dermatol., 24: 247–252.
Kohn EC, R Steis, E Sausville et al., 1990. Phase II trial of intermittent high dose recombinant interferon alpha 2a in mycosis fungoides and Sézary syndrome. J. Clin. Oncol., 8: 155–160
Kuzel TM, KI Gilyon, E Springer et al., 1990a. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J. Natl. Cancer Inst., 82: 203–207
Kuzel TM, E Springer, HH Roenigk Jr. and ST Rosen, 1990b. Mycosis fungoides: Time to define the best therapy. J. Natl. Cancer Inst., 82: 200–202.
Liberati AM, B Biscottini, M Fizotti et al., 1988. A phase I study of human natural interferon-β. J. Interferon Res., 8: 765–777
Nicolas JF, JC Balblanc, A Frappaz et al., 1989. Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a. Dermatologica, 179: 34–37
O’Connell MJ, JP Colgan, MM Oken et al., 1986. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chron ic lymphocytic leukemia. An Eastern cooperative oncology group pilot study. J. Clin. Oncol., 4: 128–136
Olsen EA, ST Rosen, RT Vollmer et al., 1989. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J. Am. Acad. Dermatol., 20: 395–407
Otte HG, A Herges and R Stadler, 1992. Kombinationstherapie mit interferon alfa 2a und PUVA bei kutanen T-Zell-Lymphomen. Hautarzt, 43: 695–699.
Papa G, ML Vegna, D Defazio et al., 1989. Recombinant interferon alpha-2a in untreated cutaneous T-cell lymphomas. J. Interferon Res., 9: Suppl. 2
Quesada JR, J Reuben, JT Manning et al., 1984. Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med., 310: 15–18
Roenigk HH Jr., TM Kuzel AP Skoutelis et al., 1990. Photo-chemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J. Invest. Dermatol., 95: 198S-205S.
Rook AH, MB Prystowsky, M Cassin et al., 1991. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Arch. Dermatol., 127: 1535–
Sherwin SA, JA Knost, S Fein et al., 1982. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA, 248: 2461–
Simoni R, R Cavalieri, G Coppola et al., 1987. Recombinant leukocyte interferon-7-2a in the treatment of mycosis fungoides. J. Biol. Regul. Homeost. Agents, 1: 93–99
Stadler R, A Mayer-da-Silva, B Bratzke et al., 1989. Interferons in dermatology. J. Am. Acad. Dermatol., 20: 650–656.
Thestrup-Pedersen K, R Hammer, K Kaltoft et al., 1988. Treatment of mycosis fungoides with recombinant interferon-2a alone and in combination with etretinate. Br. J. Dermatol., 118: 811–818
Tura S, P Mazza, PL Zinzani et al., 1987. Alpha recombinant interferon in the treatment of mycosis fungoides. Haematologica, 72: 337–340
Vegna ML, G Papa, D Defazio et al., 1990. Interferon alpha-2a in cutaneous T-cell lymphoma. Eur. J. Haematol., 45: Suppl. 52: 32–35
Vonderheid EC, R Thompson, KA Smiles and A Lattanand, 1987. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Arch. Dermatol., 123: 757–763.
Wolff JM, JA Zitelli, BS Rabin et al., 1985. Intralesional interferon in the treatment of early mycosis fungoides. J. Am. Acad. Dermatol., 13: 604–612
Young RC, 1989. Mycosis fungoides. The therapeutic search continues. N. Engl. J. Med., 321: 1822–1823.
Zachariae H and K Thestrup-Pedersen, 1990. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J. Invest. Dermatol., 95: 206S-208S.
Ziegler-Heitbrock HWL and E Thiel, 1990. Recombinant IFN-alpha in lymphomas. J. Invest. Dermatol., 95: 213S-215S.
Zinzani PL, P Mazza and F Gherlinzoni, 1988. Beta interferon in the treatment of mycosis fungoides. Haematologica, 73: 545.
Zinzani PL, P Mazza, F Gherlinzoni et al., 1991. Mycosis fungoides: A therapeutical review. Haematologica, 76: 150–161
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cerroni, L., Peris, K., Torlone, G., Chimenti, S. (1994). Use of Recombinant Interferon-α-2A in the Treatment of Cutaneous Lymphomas of T- and B-Cell Lineage. In: Lambert, W.C., Giannotti, B., van Vloten, W.A. (eds) Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin. NATO ASI Series, vol 265. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1861-7_43
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1861-7_43
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5756-8
Online ISBN: 978-1-4615-1861-7
eBook Packages: Springer Book Archive